Biomarker study of TTFields in newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial looks at how well Tumor Treating Fields (TTFields) therapy works for people with newly diagnosed glioblastoma. Researchers will study blood and tumor samples to find markers that might predict how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with glioblastoma (a type of brain cancer).
- Your doctor plans to treat you with radiation and chemotherapy, followed by Tumor Treating Fields (TTFields) therapy, and you haven't started this treatment yet.
- You are willing to provide a blood sample and tumor tissue sample for research.
- You are not pregnant, breastfeeding, or taking part in another treatment trial.
- You have health insurance in France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
This study looks at whether brain scans (MRI, PET/CT) can help predict the genetic makeup of glioblastoma, without needing more tissue samples. If you join, you'll get advanced imaging to better understand your tumor and guide future treatment decisions.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This study is testing special immune cells (called CAR-T cells) in the laboratory to see if they can attack glioblastoma tumor cells. It's a research study that uses a blood sample to grow and test these cells, and it may help find new ways to treat this type of brain tumor.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.